AboutPortfolioInvestment FocusLeadershipInsightsContact Partner With Us
Strategic Partnerships & Private Capital

Building the Future of
Healthcare Investment

MedLinks Capital partners with visionary founders and healthcare innovators to unlock private capital, forge strategic alliances, and drive transformative outcomes across the global life sciences landscape.

Explore Portfolio Our Approach
Scroll
$13.8B+
Value Created
120+
Portfolio Companies
18+
Years of Expertise
3
Continents Active
&
"We don't just invest capital — we invest conviction, strategy, and decades of deep domain expertise."
Gurdev Chimni, Managing Partner
#1
Healthcare Investment Partner
Who We Are

A Different Kind of
Capital Partner

MedLinks Capital is an investment management firm dedicated to advancing healthcare and life sciences innovation. We bring private capital, strategic networks, and hands-on partnership to help visionary founders build category-defining companies.

01
Founder-First Philosophy
We keep founders at the helm while providing the strategic scaffolding to scale with confidence.
02
Deep Domain Expertise
Decades of combined experience across biopharmaceuticals, medtech, diagnostics, and digital health.
03
Global Strategic Network
Access to a curated ecosystem of institutional partners, KOLs, and commercialisation channels worldwide.
Learn More About Us
Portfolio

Our Investments

View All Portfolio
Biopharmaceuticals
Clinical-stage biotech advancing personalised cancer immunotherapy. FDA RMAT-designated, Phase 3-ready platform leveraging genetic and cellular technologies to enhance immune response against tumours.
Current2021
Medical Devices
Pioneering robotic surgical technologies enabling complex procedures through smaller access points with greater precision. FDA Breakthrough Device designation — redefining minimally invasive surgery.
Current2022
Medical Technology
Global leader in advanced wound care co-founded by Dr. Harry Jacobson. Achieved a 12,882x MOIC and 50.7% IRR before a landmark $6.2B exit to Apax Partners in 2011.
Exited2011
Investment Focus

Areas of Deep Expertise

All Focus Areas
01
Biopharmaceuticals
Early to late-stage investments in novel therapeutics and precision medicine platforms.
Learn More
02
Digital Health
AI-powered diagnostics, health data platforms, and patient engagement technologies.
Learn More
03
Genomics & Biotech
Funding the pioneers in gene therapy, CRISPR, cell therapy, and synthetic biology platforms.
Learn More
News & Insights

Latest from MedLinks

All Insights
Investment News
Portfolio Milestones: FDA RMAT for Gradalis, Breakthrough Device for Virtuoso Surgical
MedLinks Capital's active portfolio achieves landmark regulatory milestones — validating our conviction-based approach across precision oncology, surgical robotics, and rare disease therapeutics.
May 20264 min read
Read Full Story
Industry Insight
From KCI to Gradalis: A Legacy of Healthcare Value Creation
How decades of building category-defining companies — a 12,882x MOIC on KCI, $4B Fresenius exit on Renal Care Group — inform our approach to today's breakthrough pipeline.
April 20266 min read
Read Full Story
Portfolio News
Lobe Sciences Advances Proprietary L-130 Psilocin Therapy into Clinical Trials
Lobe Sciences' non-hallucinogenic L-130 compound targets cluster headaches, PTSD, TBI, and rare neurological conditions — with patents extending beyond 2040.
March 20263 min read
Read Full Story